Asgar RangoonwalaSenior Vice President, Emerging Markets at Johnson & Johnson
Asgar Rangoonwala is currently Managing Director, Emerging Markets at Janssen EMEA. In this role, Asgar is focused on ensuring Janssen Operating Companies bring innovative medicines and healthcare solutions to patients and customers across our region, and oversees the Janssen operations in Africa, Middle East, Russia, CIS countries and Turkey. He also serves as a member of the Janssen EMEA Leadership Team and was re-elected as Chairman of RDPAC (the R&D-based Pharmaceutical Association Committee in China) by the members of RDPAC Executive Committee in 2019.
Previously, Asgar oversaw the pharmaceutical operations of Johnson & Johnson in the People’s Republic of China as President of Xian Janssen. Throughout his time in China, he proved to be an exceptional business and industry leader recognized by a number of external awards, including the 2020 Shanghai Magnolia Award, a major recognition from the city of Shanghai for foreigners who have made outstanding contributions to Shanghai’s economic and social development and international exchange.
Before moving to Beijing to lead Xian Janssen in 2016, Asgar was Managing Director of Janssen Turkey, setting Janssen on a strong path for continued success in this key market. Prior to his time in Turkey, Asgar was Director, Selling & Stakeholder Management for Janssen Germany, where his efforts paved the way for Janssen to become a more customer-oriented and value-generating organization in the highly competitive German market.
Asgar has a degree in Biology from the University of Frankfurt and joined Janssen Germany as a sales representative in 1996, and worked as Business Unit Director, Nephrology and Virology for Janssen Germany.